For the period 1990 through 2004, numbers, rates, and trends for cancer deaths in children (aged 0-14 years) and adolescents (aged 15-19 years) were analyzed, using data from the National Vital Statistics System and the US Bureau of the Census. Included for consideration were primary cancer site/leading diagnosis, US Census region, age group, sex, race, and ethnicity.
noninfectious potentially fatal diseases that continue to challenge pediatric subspecialists.
Deaths in early infancy and the toll of unintentional injuries and other forms of violence are the chief contributors to mortality rates in children in our society today, but even so, the overall number of deaths remains quite low. As others have noted, the health of children in this era is better measured by analysis of their leading morbidities rather than by their mortality rates. Too much emphasis on the latter could produce a distorted view of their most pressing needs or, even worse, create a false sense that many of their most serious problems have been resolved.
Nevertheless, we will of course always want to know the extent and causes of death in children and especially the variations in rates among subgroups of the kind enumerated in this article. As noted in the report, differences in access, late outcomes, or types of pathology more resistant to therapy may account for the findings. Each will have relevance for the evolving epidemiology of our times. 
SUMMARY
Although there is clear evidence for the value of properly used child restraint systems (CRSs) in preventing injury and death to children in motor vehicle crashes, the costeffectiveness of using the Medicaid program to provide CRSs to low-income children, who are more likely to ride unrestrained, has not been studied. These authors designed a complex model to calculate cost-effectiveness based on program costs and crash-associated outcomes for a hypothetical cohort of 100,000 children through an 8-year cycle beginning at birth. They drew on the Partners for Child Passenger Safety database (a child-focused crash database created by Children's Hospital of Philadelphia and the State Farm Mutual Automobile Insurance Company) and other sources to estimate crash-related injury and fatality rates according to use of restraints, seat belts, or no restraints for age cohorts representing infants, toddlers (1-3 years), and young children (4-7 years). Other data from the literature provided rates of restraint usage for low-income children in general and after they participated in programs that disbursed CRSs and educated about their use (for the latter case, the Task Force on Community Preventive Services' review of 11 articles showed a 23% increase in correct CRS use for infants and toddlers and 35% for young children). Program costs were derived from information on two disbursement and education programs and the actual consumer costs of restraints. Both medical and societal (parental work loss and future productivity loss) costs were included in the calculation of crash-associated outcomes. A Medicaid CRS disbursement and education program would avert 17 deaths and 81 serious and 319 minor injuries over an 8-year cycle; annually, it would save about $1 million in medical costs, $94,000 in parental work loss costs, and $2.7 million in loss-of-future productivity. Cumulative costs of implementing the program over the 8 years would be $10 million. Net cumulative costs (after subtracting medical costs saved) would be $3.2 million or $32 per beneficiary ($4 annually). For the Medicaid program, the cost of each death averted would be $561,534; for each life-year saved, it would be $16,928 (no calculation was done for injuries averted).
For society, however, at 8 years, there would be savings of $90,750 for each death averted and $2756 for each life-year saved.
A comparison of this cost-effectiveness analysis with those in the literature for six different childhood vaccines showed that all were cost saving to society. For insurers, the CRS disbursement program would be more cost-effective than any of the vaccines except those for Hemophilus influenza B and measles-mumps-rubella.
COMMENTARY
In view of the strong pressure at all levels of government to reduce the cost of the Medicaid program, an analysis of a new expense that in the short term does not show a direct cost-benefit to the Medicaid program itself might not carry much weight with policy makers. However, the careful and detailed analysis of the longterm benefits of CRS disbursement (the summary above did not mention that alternative outcomes calculated from variations on the base assumptions were also examined), along with the compelling idea of comparing the benefit to that of vaccines should inspire a second look.
Note that the ratio of serious injuries to deaths prevented is almost 5 to 1. One element of serious injury not included in this model is the possibility of long-term disability with its attendant medical and societal costs. It is not unreasonable to suppose that factoring those into the cost-effectiveness calculation might tip the balance toward actual savings to the Medicaid program.
A more fundamental consideration deals with the nature of the Medicaid program itself. Commercial insurers can use cost-effectiveness analyses to predict the economic viability as well as the profits of their enterprise. Societal benefits will not enter into their calculations. However, Medicaid is not merely public insurance. Its mission is a societal one-to contribute to the health of its recipients by providing access to care. "Society" not only supports Medicaid through its taxes but is the recipient of Medicaid's societal benefits. Hence, with regard to Medicaid, analyzing cost-effectiveness for medical savings separately from societal savings creates a false dichotomy that could subvert a convincing argument in support of a needed and valuable program.
Medicaid support of preventive services for children has been part of the program almost since it began. For it to provide child restraint systems would be a fitting addition, both literally and figuratively. 
